Ember Biosci manufactures microfluidic screening devices that accelerate antibody candidate selection for pharmaceutical development, cutting screening timelines from months to weeks. The technology was developed at Macquarie University's Institute for Molecular Bioscience and is now being validated by a leading Australian biotech CRO.